By Lori Abrams
Those who know me understand the value I put on bringing the voice of the patient and caregiver into the drug development process. They also know that I believe that todays terminology phrases like patient-centricity, patient at the center, and other sexy mottos is sometimes used by organizations to show the world that the patient is at the forefront of everything they do. But are they really? Is patient feedback on a protocol enough to prove that their voices are heard? Is providing input on an informed consent what a patient really wants to do? Maybe.
How often has an organization asked the patient and caregiver how they would like to contribute to a drug development program? If they could do anything to help bring a drug to the market, what would that look like? Moreover, if a trial participant could provide ongoing feedback that improved the patient experience, what would they contribute, and how might the trial change?
Lets try it now. I am humbled to introduce readers to Amy Butler. Together, we are going to try to shed some light on the drug development process from the perspective of a brave woman who has participated in five clinical trials. First, a brief summary of Amys experience
Amy was a medical assistant for a large obstetrics and gynecology practice near her home in McHenry, IL, where she lives with her husband and two children (along with two cats, a quacker parrot, and a corgi puppy). Advocacy has always been a part of her life, as she has a brother who is developmentally disabled. But she never expected that her biggest challenge as an advocate would be to try to save her own life.
In 2014, at 44 years of age, Amy was diagnosed with stage IV colon cancer with metastasis to the liver. At the Mayo Clinic, she had a right hemicolectomy and liver resection, along with a prophylactic hysterectomy because she discovered through genetic testing that she had a CHEK2 variant. She underwent six months of Folfox chemotherapy with Avastin and was deemed cancer-free. Nine months later, a follow-up scan revealed that she had metastatic disease in both lungs. She began Folfiri with Avastin; however, after about 10 months, scans started showing progression in her lungs.
Against her Mayo Clinic oncologists advice, she began looking into clinical trials. Fortunately, her support group Colontown (see related article) provided her with science-based information about clinical trials. Her local oncologist referred her to the University of Chicago. Over the next two years, she participated in four clinical trials. Three of the trials were immunotherapy in combination with other drugs and one was an antibody trial. Due to progression, she returned to her local oncologist and revisited standard chemotherapy for a few months, with no success. Recently, Amy was approved to start her fifth clinical trial.
Amy was kind enough to answer my questions about her journey, providing an unvarnished look at clinical trials from a patients perspective and shedding light on aspects of the clinical trial process in desperate need of improvement.
Lori Abrams: You were at the Mayo Clinic and clinical trial participation was not supported. Can you describe what occurred and why?
Amy Butler: I was at Mayo Clinic for a follow-up visit and my oncologist was going over my latest CT scan results. The scans showed that my cancer was progressing while on Folfiri chemotherapy. Upon hearing this news, I told my oncologist that I thought it was time to look into clinical trials. He didnt agree with me. His recommendation was I should take a break from chemotherapy, as I was completely worn out from treatment. He felt that after a month off I would be strong enough to start treatment again in hopes of keeping my cancer at bay. Knowing that I had a mutation in the KRAS gene, I understood that I had fewer treatment options and this terrified me. I didnt want to settle; I wanted more options. After further discussion, I was told that Mayo Clinic had no clinical trials to offer me and there was no mention of any other facilities that I should consult with.
Abrams: How did it feel when you were not offered alternative options to standard care by your Mayo oncologist? What were your next steps?
Butler: It was terrible; I felt so alone. Here I was at one of the countrys premier medical facilities, and all Im offered was to continue standard of care chemotherapy, even though it clearly wasnt working anymore. My next step was to see my local oncologist and discuss my recent scans with him. This conversation was quite different from my conversation at Mayo Clinic. My local oncologist really listened to my concerns about continuing with the same chemotherapy treatments and when I asked him about clinical trials, he was on board. I walked out of that appointment with a referral to the University of Chicago. Two weeks later, I was signing a consent form for my first clinical trial.
Abrams: How and when did you find Colontown?
Butler: When I was diagnosed with stage IV colon cancer in 2014, I followed all the rules. One of those rules was to stay off the internet. In 2016, when I learned that the cancer had metastasized to my lungs, I threw that rule out the window and began looking for answers. I came across a blog called Adventures in Living Terminally Optimistic by Tom Marsilje. Tom was an oncology researcher who was also diagnosed with colon cancer at a young age. I was inspired by Toms blog; it filled me with hope again. On his blog, Tom mentioned many colon cancer support groups. I was overwhelmed with the amount of support out there. I couldnt believe that my doctors never mentioned or recommended them.
I contacted Tom and we had a great discussion about new treatments coming for colon cancer patients. He talked to me about the different support groups and recommended that I join Colontown.
Abrams: Colontown helped you understand clinical trials. What type of information did they provide? Did they provide navigation to clinical trials? How did they help you to better understand your disease?
Butler: Colontown became my lighthouse in the dark. First, let me explain how Colontown works. When you join Colontown, the administrators invite you to join private patient-lead neighborhoods. Each neighborhood is based on the stage, tumor mutations, and metastatic disease. The clinical trial neighborhoods are broken down into groups based on microsatellite instability (MSI) status as well as mutations.
Through Colontown, I was educated about what my MSI status (mine being microsatellite stable, or MSS) and my KRAS mutation meant. Not only was I able to grasp my disease, I also met wonderful people who were going through the same thing. Within the MSS clinical trial neighborhood there is a link to the Late Stage Trial Finder that was curated by Fight CRC and created by Marsilje, a scientist and Colontown member.
Abrams: You have participated in five clinical trials. Were you asked to provide feedback (good or bad) before, during, or after your participation?
Butler: The answer to this is a resounding no. The only feedback Im asked to provide is what my side effects are during treatment.
Abrams: If you could be an advisor to drug development process at a company, what would that look like?
Butler: I believe that a patient has the right to know the results of any specialized testing that was done. Ive had to have multiple lung biopsies in clinical trials, and I wasnt told why or what they were looking for. Ive had blood draws where 15 tubes of blood were taken, and I have no idea if anything interesting was found. I think patients deserve to get some results. Pharmaceutical companies should issue symptom diaries for the trials because a patient may forget how they were feeling by the time of their next appointment. A patient wants to know how their participation helped in the clinical trial.
Abrams: Were the results of the first four studies shared with you after the study closed? Did any of the sites ever reach out with results?
Butler: No; sadly, Ive never heard any results from the clinical trials Ive participated in. I feel that the facility site should get the results and share it with the patients who participated in them.
Abrams: Would you describe some of the best practices that made you feel safe, valued, and appreciated at a clinical trial site?
Butler: The facilities nurse navigators are amazing. They are your sounding board and liaison between the patient, doctors, and pharmaceutical company. The nurses who administer the treatments are some of the kindest people that I have ever met. In one of the clinical trials I participated in, I was required to stay near the facility for 10 days for daily blood draws. This meant that I couldnt go home because I lived too far away. When I went to the clinic on a Saturday for my blood draw, one of the nurses brought her puppy and they were waiting outside for me. She knew that I was homesick, and her cuddly puppy gave me the boost I needed to get through my stay.
Abrams: Conversely, would you describe experiences that made your participation difficult and or frustrating?
Butler: Overall, the waiting time is the most frustrating part of participating in a clinical trial, especially in the larger clinics. The waiting time between the signed consent and the start date, time spent sitting in waiting rooms for blood draws and CTs, and anxiously waiting for test results.
Abrams: If you could provide feedback to a sponsor (pharmaceutical company) on how to design and execute a better clinical trial for people with cancer, what would you tell them?
Butler: I would ask the pharmaceutical companies to send surveys to the treatment sites for patients to fill out periodically. This would give the patients an opportunity to give their opinions while still remaining unidentified. I would like the sponsors to make it easier for the patients to get results of the clinical trial that they participated in.
Abrams: Have you heard the phrases I mentioned above? Patient-centricity, patient at the center, etc.? What do they mean to you?
Butler: Yes, I am familiar with those terms. For me, patient-centricity means that I have some control in my clinical trial journey. Not only am I being treated, but I am being cared about. Im not just a number.
Abrams: Amy, what do you want people to know about clinical trials and/or participating in clinical trials that we have not discussed?
Butler: I think that clinical trials should be part of the discussion early on in a patients cancer journey. Too many patients are waiting until its too late to start clinical trials because they are made to feel that its taboo to bring it up to their oncologist. I want the pharmaceutical companies to never lose sight that we are people who are desperately trying to beat cancer, or at least be able to live longer with cancer. We cant afford to waste time.
Abrams: This is Amys journey, not mine. Therefore, Amy will provide the ending to this article. I hope you have been touched by Amys words, strength, and courage. Together, we can continue to improve clinical research for the patients. They are our friends, our family members, and ourselves.
Butler: Although my participation in clinical trials has not cured me, I do believe they have extended my life. I was given a 30 percent chance to live five years when I was diagnosed, and here I am almost five years later. My disease has recently taken a dark turn, as I just learned that my fifth clinical trial has failed. My tumors have grown and now I have bone involvement. My treatment options are dwindling, but I refuse to give up because when it gets down to it, I just want to live.
Postscript: On the day of discontinuation of clinical trial No. 5, Amy decided that going back to a standard course of therapy was not going to be her path. She inquired about an NIH clinical trial. The oncologist agreed that this was a good idea. Once again, Amy left a doctors office with a good idea, but without a referral or contact name or number. However, there is good news. The following week, she was screened for a trial at NIH, and eight days later, she was accepted to be a patient participant.
About The Author:
Lori Abrams is senior director of Patient Advocacy, a new division at WCG Clinical. She previously was in R&D at Bristol-Myers Squibb for 20 years, the last five as director of Diversity and Patient Engagement. This group integrated the voice of the patient and caregiver into the clinical trial process, developed relationships in the disease-based and minority-focused communities, and helped colleagues understand the challenges of those living with diseases. You can email her at email@example.com.
- Global Thalassemia Treatment Market is estimated to be US$ 14.7 billion by 2030 with a CAGR - GlobeNewswire - May 3rd, 2021
- Cell and Gene Therapy Market Opportunities, Recent Industry Size and Share Analysis With Forecast To 2027 | Dendreon, Vericel, Spark Therapeutics,... - May 3rd, 2021
- Searching for the Causes and Cures of Spinocerebellar Ataxias - University of Utah Health Care - May 3rd, 2021
- Global Negative Pressure Wound Therapy Market In-deep Analysis And Experts Review Report 2021-2024 Clark County Blog - Clark County Blog - May 3rd, 2021
- Antidepressants Market Size 2021 | Is Projected to Reach USD 18.29 Billion by 2027, Exhibiting a CAGR of 2.9% during 2020-2027 - GlobeNewswire - May 3rd, 2021
- Johnson & Johnson's COVID-19 vaccine has been paused in Colorado. Here's what you need to know. - The Denver Channel - April 18th, 2021
- Global Alpha Thalassemia Market 2021 Industry Insights, Drivers, Top Trends, Global Analysis And Forecast to 2027 NeighborWebSJ - NeighborWebSJ - April 18th, 2021
- Canavan Disease Treatment Market Growing Demand with Innovative Ideas Adopted by Key Players Johnson & Johnson Services, Inc., GlaxoSmithKline... - April 18th, 2021
- Cystinuria Treatment Market In-depth Research Covering Share Analysis, Industry Overview and Forecast | Key Players Retrophin, Inc, Mission Pharmacal... - April 18th, 2021
- Global Botulinum Toxin Market Size 2021 | To Hit USD 7.71 Billion at 7.5% CAGR by 2027; Increasing Awareness about the Therapeutic Benefits of Botox... - April 18th, 2021
- Adrenoleukodystrophy Treatment Market to Rise with Impressive CAGR | Players Viking Therapeutics, Nutra Pharma Corporation, Genetix Biotech Asia Pvt.... - April 18th, 2021
- Gene Therapy for CNS Disorders Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Gilead (Kite Pharma), Amgen (BioVex), Novartis,... - April 4th, 2021
- Top Executives from AveXis Join New Gene Therapy Venture -- This Time Targeting Tens of Millions More Patients - PRNewswire - April 4th, 2021
- Gene Therapy for Hemophilia Market will Reach Thriving Value by 2019 to 2028 SoccerNurds - SoccerNurds - April 4th, 2021
- Hemophilia Treatment Market Analysis to 2025 - Growth Trends and Changes Influencing the Industry - Technology Magazine - February 9th, 2021
- Alpha Thalassemia Market Global Production, Growth, Share, Demand and Applications Forecast to 2027 NeighborWebSJ - NeighborWebSJ - February 9th, 2021
- Global Retinitis Pigmentosa (Retinitis) Market demand with COVID-19 recovery analysis 2021 better delivery process to boost market growth by 2026 KSU... - February 4th, 2021
- ASCO Names Molecular Profiling in GI Cancers as Advance of the Year - OncLive - February 4th, 2021
- Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D'OXYVA for Rapid,... - February 2nd, 2021
- Parkinson's disease treatment Market Global Industry Analysis, Size, Share, Trends, Segmentation and Forecast 2021 2027 KSU | The Sentinel... - January 27th, 2021
- The Head And Neck Cancer Therapeutics Market to shirk economic slowdown between 2016 and 2024 Murphy's Hockey Law - Murphy's Hockey Law - January 27th, 2021
- Global Phenylketonuria (PKU) Treatment Market Detailed Analysis of Current Industry Figures with Forecast Growth By Top Competitors:American Gene... - January 23rd, 2021
- Global MRD (Minimal Residual Disease) Testing Market Report 2020-2025: One of the Most Rapidly Evolving and Dynamic Markets - GlobeNewswire - January 23rd, 2021
- Aerosol Masks Market to Witness Huge Growth by 2030 - KSU | The Sentinel Newspaper - January 19th, 2021
- Global Clinical Laboratory Services Market Analysis With Key Players, Applications, Trends And Forecasts 2028 - KSU | The Sentinel Newspaper - January 19th, 2021
- Alpha Thalassemia Market Outlook 2021 Witnessing Enormous Growth with Recent Trends & Demand | Regions are Bluebird Bio, Novartis, Kiadis Pharma,... - January 5th, 2021
- FABRY DISEASE MARKET 2020 2023 PROJECTED TO GROW RADIANTLY BY TOP PLAYERS REVENUE AND GROWTH RATE - Factory Gate - January 5th, 2021
- 2020 Highlights the Disparities and Discrepancy of Sickle Cell Care - MD Magazine - December 31st, 2020
- Gene Therapy Market 2020: Demand Analysis, Key Players, Trends, Sales, Supply, Deployment Model, Segments, Organization Size, Production, Revenue Data... - December 31st, 2020
- Global Stem Cell Manufacturing Market Research Study including Growth Factors, New Top Players, Competitive Analysis by regions from 2020 to 2027 -... - December 31st, 2020
- Global Brain Tumor Treatment Market Proceeds To Witness Huge Upswing Over Assessment Period by 2025 - The Courier - December 19th, 2020
- Global Gene Therapy Market Report 2020-2030 Featuring Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics, Voyager Therapeutics,... - December 18th, 2020
- Gene Therapy Market Worth USD 35.67 Billion at 33.6% CAGR; Rising Prevalence of Spinal Muscular Atrophy to Augment Growth: Fortune Business Insights -... - December 18th, 2020
- Worldwide Industry for Cystic Fibrosis Therapeutics to 2025 - Players Include AbbVie, Alaxia and Alcresta Therapeutics Among Others - Stockhouse - December 18th, 2020
- Elidah Becomes the Only US Company to Win a Top Ten Prize in a Global Start-up Competition, Advancing Recognition for Women's Health - PRNewswire - December 18th, 2020
- Global Gene Therapy Market Report 2020: Non-COVID-19 Care Delivery Bears the Brunt of the Pandemic - Gene Therapy Market Slumps by -13.6% -... - December 3rd, 2020
- Global Gene Therapy Market Report 2020-2027: Market is Projected to Reach a Revised $3.3 Billion - GlobeNewswire - December 3rd, 2020
- 2020 Top 10 Innovations - The Scientist - December 3rd, 2020
- Global Regenerative Medicine Market to Rise Impressively at 26.1% CAGR and Hit USD 151,949.5 Million by 2026; Integra's Latest Product Offerings to... - December 3rd, 2020
- Precision Cancer Therapies Market Report 2020: Top Companies, Regions, Driving Force and Forecast 2026 - The Market Feed - December 3rd, 2020
- Hemophilia Treatment Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19) - Cheshire Media - December 3rd, 2020
- Global Contract Cell and Gene Therapy Manufacturing Market Report 2020-2026: CDMO Categorization - Primed for Business Model Disruption - Benzinga - November 26th, 2020
- Internet hawkers of stem cell therapies raising red flags - Ophthalmology Times - November 26th, 2020
- Details are everything: Where is Ottawas COVID-19 vaccination plan? - The Globe and Mail - November 26th, 2020
- Impact of Covid 19 On Brain Tumor Treatment Market 2020 Industry Challenges Business Overview And Forecast Research Study 2026 - The Market Feed - November 26th, 2020
- Global Gene Therapy Industry - GlobeNewswire - November 20th, 2020
- Children's Hospital delivers life-saving gene replacement therapy to infant - Loma Linda University Health - November 20th, 2020
- Global Precision Cancer Therapies Market 2020: Analysis, Industry Growth, Current Trends and Forecast till 2025 - The Daily Philadelphian - November 20th, 2020
- Cutting-edge Treatment Offers Hope to Infant With Spinal Muscular Atrophy - Adventist Review - November 20th, 2020
- Molecular Testing With Universal Method Comparable to Traditional Method in Hereditary Solid Tumors - Targeted Oncology - November 20th, 2020
- Alpha Thalassemia Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted By the Competitors |... - November 20th, 2020
- Intrathecal Pumps Market 2020 Industry Size and Share Evolution to 2026 by Growth Insight, Trends - The Daily Philadelphian - November 20th, 2020
- $30 billion to fight COVID-19 over next five years - Sydney Morning Herald - November 20th, 2020
- Global Contract Cell and Gene Therapy Manufacturing Market 2020-2026: Automation Deployed to Contain Cost of Goods Sold and Vector Manufacturing... - November 12th, 2020
- Gene Therapy Market Size Is Estimated to Grow at a CAGR of 40.7% By 2025 | Sales Statistics, Future Trends, Business Overview and COVID-19 Impact... - November 12th, 2020
- Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU -... - November 12th, 2020
- Magnetic Resonance Imaging Market Growth Estimation, Future Insights, Applications, Key Players, Size Analysis, COVID-19 Impact and MRI Industry... - November 12th, 2020
- Choroideremia Treatment Market Share Analysis by Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc - Sunrise Nigeria - November 12th, 2020
- Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU - GlobeNewswire - November 11th, 2020
- Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU | DNA... - November 11th, 2020
- COVID vaccine to be rolled out within months: Hunt - Daily Mercury - November 11th, 2020
- Blockchain offers advanced therapy tracking - Bioprocess InsiderBioProcess - BioProcess Insider - November 5th, 2020
- Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights - GlobeNewswire - November 5th, 2020
- Lynparza approved in the EU as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer | Small Molecules | News... - November 5th, 2020
- Predictive Biomarkers Market Growth Sales Revenue Analysis 2020-2025 - The Think Curiouser - November 5th, 2020
- Retinitis Pigmentosa (Retinitis) Market Report 2020 (COVID-19 Impact Analysis) By Segmentations, Key Company Profiles & Demand Forecasts to 2020 ... - November 5th, 2020
- Hyperbaric Oxygen Therapy (HBOT)Market: Is Covid19 testing the healthcare industry? - PRnews Leader - October 29th, 2020
- Coronavirus Outbreak: C-Arms Industry Fights Back with Well-defined Business Strategies - PRnews Leader - October 29th, 2020
- The good news about breast cancer - The Gazette - October 29th, 2020
- Retinitis Pigmentosa (Retinitis) Market Analysis by 24 Key Players, Types, Applications and Growth Opportunities to 2025 - The Think Curiouser - October 29th, 2020
- Choroideremia Treatment Market Trend & Growth by Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc - PRnews Leader - October 24th, 2020
- Precision Cancer Therapies Market Research on Precision Cancer Therapies Market 2019 and Analysis to 2025 - PRnews Leader - October 24th, 2020
- Clinical Laboratory Services Market 2020-2027 Strong Revenue and Competitive Outlook By Top Leaders : Mayo Foundation for Medical Education and... - October 17th, 2020
- CHOROIDEREMIA TREATMENT MARKET BUSINESS GROWTH BY COPERNICUS THERAPEUTICS, INC, WIZE PHARMA INC, SPARK THERAPEUTICS, INC - PRnews Leader - October 17th, 2020
- Cryopreservation Equipment Market: Increase in Demand for Regenerative Medicines to Accelerate Market Growth - BioSpace - October 10th, 2020
- Cartilage Repair/ Cartilage Regeneration Market worth $1,603 million by 2025 - Exclusive Report by MarketsandMarkets - PR Newswire UK - October 10th, 2020
- Pediatric Neuroblastoma Treatment Market Share Worldwide Industry Growth, Size, Statistics and Opportunity During 2020 to 2026 - Press Release -... - October 10th, 2020
- NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank - Watauga Democrat - October 7th, 2020
- What Will Be Driving Growth of Alpha Thalassemia market Near Future By Top Vendors Like | Bluebird Bio, Novartis, Kiadis Pharma, Acceleron Pharma ,... - October 7th, 2020
- Cancer Therapy Market Research by 2020 Top Countries Data, Key Players, Industry Revenue, Demand Status and Investments Plans Forecast to 2024 - The... - October 7th, 2020